Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER/CDER Reorganization Will Lengthen Reviews, Ex-FDAer Warns HHS

Executive Summary

FDA's proposed transfer of therapeutic biological product reviews to the Center for Drug Evaluation & Research could lead to longer review times due to decreased emphasis on staff research, a former Center for Biologics Evaluation & Research division director told HHS
Advertisement

Related Content

CBER-CDER Transition: FDA Creating Template For Product Review Transfer
CBER-CDER Transition: FDA Creating Template For Product Review Transfer
Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
CBER/CDER Merger Is One Topic Of Erbitux Discussions In House Cmte.
Advertisement
UsernamePublicRestriction

Register

PS040532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel